+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Generalized Anxiety Disorder Market by Mode Of Action, Pricing Strategy, Distribution Channel, Healthcare Providers - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 190 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6016467
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Generalized Anxiety Disorder Market grew from USD 2.13 billion in 2023 to USD 2.23 billion in 2024. It is expected to continue growing at a CAGR of 5.42%, reaching USD 3.09 billion by 2030.

Generalized Anxiety Disorder (GAD) is a chronic mental health condition characterized by excessive and uncontrollable worry about various aspects of life. GAD significantly impacts individuals' daily functioning and quality of life, thereby increasing the demand for effective treatments. The necessity for GAD therapies is propelled by the rising prevalence of mental health disorders and increased awareness of mental well-being. Application involves pharmaceuticals, such as benzodiazepines and SSRIs, along with cognitive behavioral therapy (CBT), which remain the mainstay treatments. End-use scope includes healthcare institutions, mental health clinics, and homecare. Market growth is influenced by advancements in pharmacological research, government initiatives supporting mental health programs, and a shift towards telemedicine increasing accessibility to therapy. Moreover, the integration of digital solutions like mobile apps for mindfulness and CBT offer robust potential opportunities for engagement. The expansion of personalized medicine, aided by genetic studies, provides avenues for targeted therapies, presenting significant opportunities for stakeholders. However, the market faces limitations such as stigmatization of mental health issues, which can hinder treatment uptake. Regulatory hurdles and high costs of drug development also pose challenges, along with side effects associated with current medications that limit their long-term use. Another challenge is the underdiagnosis of GAD, which can impede market growth. For innovation, the focus should be on developing non-invasive therapies, leveraging AI for diagnostic and treatment personalization, and improving the safety profiles of existing drugs. Innovative research in neurobiology and psychopharmacology holds promise for uncovering new therapeutic targets. The market is dynamic, with a growing emphasis on holistic and integrative approaches in mental health, highlighting the need for businesses to adopt flexible strategies. Companies should prioritize collaborations with tech firms and research institutions to lead in novel therapeutic developments and widen their market footprint.

Understanding Market Dynamics in the Generalized Anxiety Disorder Market

The Generalized Anxiety Disorder Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Expansion of telemedicine and telepsychiatry services facilitating convenient treatment for generalized anxiety disorder
    • Government initiatives and funding for mental health programs boosting market growth
    • Integration of behavioral therapies and psychotherapies in treatment regimens enhancing patient outcomes
    • Increasing collaborations between pharmaceutical companies and research institutions to develop advanced treatments
  • Market Restraints
    • Limited insurance coverage and reimbursement issues affecting access to generalized anxiety disorder treatments
  • Market Opportunities
    • Advancements in pharmacological treatments for generalized anxiety disorder yielding high market potential
    • Exploration of mindfulness and cognitive-behavioral therapy apps targeting anxiety disorders
    • Increasing investment in mental health awareness campaigns driving market growth in anxiety-related products
  • Market Challenges
    • Social stigma surrounding mental health conditions impacting patient diagnosis and treatment-seeking behavior

Exploring Porter’s Five Forces for the Generalized Anxiety Disorder Market

Porter’s Five Forces framework further strengthens the insights of the Generalized Anxiety Disorder Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Generalized Anxiety Disorder Market

External macro-environmental factors deeply influence the performance of the Generalized Anxiety Disorder Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Generalized Anxiety Disorder Market

The Generalized Anxiety Disorder Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Generalized Anxiety Disorder Market

The Generalized Anxiety Disorder Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Generalized Anxiety Disorder Market

The Generalized Anxiety Disorder Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Generalized Anxiety Disorder Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alkermes plc, Allergan plc, AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, H. Lundbeck A/S, Jazz Pharmaceuticals plc, Johnson & Johnson, Merck & Co., Inc., Novartis International AG, Otsuka Holdings Co., Ltd., Pfizer Inc., Roche Holding AG, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Vanda Pharmaceuticals Inc..

Market Segmentation & Coverage

This research report categorizes the Generalized Anxiety Disorder Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Mode Of Action
    • Gamma-Aminobutyric Acid (GABA) Receptors
    • Norepinephrine Modulators
    • Serotonin Modulators
  • Pricing Strategy
    • Economy Pricing
    • Penetration Pricing
    • Premium Pricing
  • Distribution Channel
    • Hospitals
    • Online Pharmacies
    • Retail Pharmacies
  • Healthcare Providers
    • Primary Care Physicians
    • Psychiatrists
    • Therapists
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Expansion of telemedicine and telepsychiatry services facilitating convenient treatment for generalized anxiety disorder
5.1.1.2. Government initiatives and funding for mental health programs boosting market growth
5.1.1.3. Integration of behavioral therapies and psychotherapies in treatment regimens enhancing patient outcomes
5.1.1.4. Increasing collaborations between pharmaceutical companies and research institutions to develop advanced treatments
5.1.2. Restraints
5.1.2.1. Limited insurance coverage and reimbursement issues affecting access to generalized anxiety disorder treatments
5.1.3. Opportunities
5.1.3.1. Advancements in pharmacological treatments for generalized anxiety disorder yielding high market potential
5.1.3.2. Exploration of mindfulness and cognitive-behavioral therapy apps targeting anxiety disorders
5.1.3.3. Increasing investment in mental health awareness campaigns driving market growth in anxiety-related products
5.1.4. Challenges
5.1.4.1. Social stigma surrounding mental health conditions impacting patient diagnosis and treatment-seeking behavior
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Generalized Anxiety Disorder Market, by Mode Of Action
6.1. Introduction
6.2. Gamma-Aminobutyric Acid (GABA) Receptors
6.3. Norepinephrine Modulators
6.4. Serotonin Modulators
7. Generalized Anxiety Disorder Market, by Pricing Strategy
7.1. Introduction
7.2. Economy Pricing
7.3. Penetration Pricing
7.4. Premium Pricing
8. Generalized Anxiety Disorder Market, by Distribution Channel
8.1. Introduction
8.2. Hospitals
8.3. Online Pharmacies
8.4. Retail Pharmacies
9. Generalized Anxiety Disorder Market, by Healthcare Providers
9.1. Introduction
9.2. Primary Care Physicians
9.3. Psychiatrists
9.4. Therapists
10. Americas Generalized Anxiety Disorder Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Generalized Anxiety Disorder Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Generalized Anxiety Disorder Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. GENERALIZED ANXIETY DISORDER MARKET RESEARCH PROCESS
FIGURE 2. GENERALIZED ANXIETY DISORDER MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2023 VS 2030 (%)
FIGURE 7. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2023 VS 2030 (%)
FIGURE 9. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 11. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2023 VS 2030 (%)
FIGURE 13. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. GENERALIZED ANXIETY DISORDER MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. GENERALIZED ANXIETY DISORDER MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. GENERALIZED ANXIETY DISORDER MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GENERALIZED ANXIETY DISORDER MARKET DYNAMICS
TABLE 7. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY GAMMA-AMINOBUTYRIC ACID (GABA) RECEPTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY NOREPINEPHRINE MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SEROTONIN MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ECONOMY PRICING, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PENETRATION PRICING, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PREMIUM PRICING, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRIMARY CARE PHYSICIANS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PSYCHIATRISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY THERAPISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 28. ARGENTINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 32. BRAZIL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 33. BRAZIL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 36. CANADA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 37. CANADA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 38. CANADA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. CANADA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 40. MEXICO GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 41. MEXICO GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 42. MEXICO GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. MEXICO GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 49. ASIA-PACIFIC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 50. ASIA-PACIFIC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 53. ASIA-PACIFIC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 54. AUSTRALIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 55. AUSTRALIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 56. AUSTRALIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. AUSTRALIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 58. CHINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 59. CHINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 60. CHINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. CHINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 62. INDIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 63. INDIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 64. INDIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. INDIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 66. INDONESIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 67. INDONESIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 68. INDONESIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. INDONESIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 70. JAPAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 71. JAPAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 72. JAPAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. JAPAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 74. MALAYSIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 75. MALAYSIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 76. MALAYSIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. MALAYSIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 78. PHILIPPINES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 79. PHILIPPINES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 80. PHILIPPINES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. PHILIPPINES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 82. SINGAPORE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 83. SINGAPORE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 84. SINGAPORE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. SINGAPORE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 86. SOUTH KOREA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 87. SOUTH KOREA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 88. SOUTH KOREA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. SOUTH KOREA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 90. TAIWAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 91. TAIWAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 92. TAIWAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. TAIWAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 94. THAILAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 95. THAILAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 96. THAILAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. THAILAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 98. VIETNAM GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 99. VIETNAM GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 100. VIETNAM GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. VIETNAM GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 107. DENMARK GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 108. DENMARK GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 109. DENMARK GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. DENMARK GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 111. EGYPT GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 112. EGYPT GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 113. EGYPT GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. EGYPT GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 115. FINLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 116. FINLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 117. FINLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. FINLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 119. FRANCE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 120. FRANCE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 121. FRANCE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. FRANCE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 123. GERMANY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 124. GERMANY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 125. GERMANY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. GERMANY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 127. ISRAEL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 128. ISRAEL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 129. ISRAEL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. ISRAEL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 131. ITALY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 132. ITALY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 133. ITALY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. ITALY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 135. NETHERLANDS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 136. NETHERLANDS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. NETHERLANDS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 139. NIGERIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 140. NIGERIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 141. NIGERIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. NIGERIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 143. NORWAY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 144. NORWAY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 145. NORWAY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. NORWAY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 147. POLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 148. POLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 149. POLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. POLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 151. QATAR GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 152. QATAR GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 153. QATAR GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. QATAR GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 167. SPAIN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 168. SPAIN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 169. SPAIN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. SPAIN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 171. SWEDEN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 172. SWEDEN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. SWEDEN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 175. SWITZERLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 176. SWITZERLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 177. SWITZERLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. SWITZERLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 179. TURKEY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 180. TURKEY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 181. TURKEY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. TURKEY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 191. GENERALIZED ANXIETY DISORDER MARKET SHARE, BY KEY PLAYER, 2023
TABLE 192. GENERALIZED ANXIETY DISORDER MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Generalized Anxiety Disorder Market, which are profiled in this report, include:
  • AbbVie Inc.
  • Alkermes plc
  • Allergan plc
  • AstraZeneca plc
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • Jazz Pharmaceuticals plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Vanda Pharmaceuticals Inc.

Methodology

Loading
LOADING...

Table Information